MCID: HR2002
MIFTS: 19

Her2-Receptor Negative Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Her2-Receptor Negative Breast Cancer

MalaCards integrated aliases for Her2-Receptor Negative Breast Cancer:

Name: Her2-Receptor Negative Breast Cancer 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0060080

Summaries for Her2-Receptor Negative Breast Cancer

MalaCards based summary : Her2-Receptor Negative Breast Cancer is related to breast benign neoplasm and gallbladder cancer. An important gene associated with Her2-Receptor Negative Breast Cancer is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Development HGF signaling pathway and Pathways in cancer. The drugs Bevacizumab and Angiogenesis Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include breast, and related phenotype is Decreased viability with paclitaxel.

Related Diseases for Her2-Receptor Negative Breast Cancer

Diseases in the Her2-Receptor Positive Breast Cancer family:

Her2-Receptor Negative Breast Cancer

Diseases related to Her2-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 breast benign neoplasm 9.7 BCL2L1 ERBB2
2 gallbladder cancer 9.6 BCL2L1 ERBB2
3 hartnup disorder 9.6 BCL2L1 ERBB2
4 zimmermann-laband syndrome 2 9.5 BCL2L1 ERBB2
5 exudative vitreoretinopathy 7 9.5 BCL2L1 ERBB2
6 glioblastoma 3 9.4 BCL2L1 ERBB2
7 nail disorder, nonsyndromic congenital, 3, 9.2 BCL2L1 ERBB2

Graphical network of the top 20 diseases related to Her2-Receptor Negative Breast Cancer:



Diseases related to Her2-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Her2-Receptor Negative Breast Cancer

GenomeRNAi Phenotypes related to Her2-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 BCL2L1 ERBB2
2 Decreased viability with paclitaxel GR00179-A-2 8.92 BCL2L1
3 Decreased viability with paclitaxel GR00179-A-3 8.92 BCL2L1

Drugs & Therapeutics for Her2-Receptor Negative Breast Cancer

Drugs for Her2-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 2 216974-75-3
2 Angiogenesis Inhibitors Phase 4,Phase 2
3 Angiogenesis Modulating Agents Phase 4,Phase 2
4 taxane Phase 4
5
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
6
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
7
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
8
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
9
Metronidazole Approved Phase 2 443-48-1 4173
10 Estrogens Phase 2
11 Mitogens Phase 2
12 Albumin-Bound Paclitaxel Phase 2
13 Antimitotic Agents Phase 2
14 Antineoplastic Agents, Phytogenic Phase 2
15 Hormones Phase 2
16 Antibodies Phase 2
17 Antibodies, Monoclonal Phase 2
18 Antimetabolites Phase 2
19 Antimetabolites, Antineoplastic Phase 2
20 Immunoglobulins Phase 2
21
Everolimus Approved 159351-69-6 6442177
22
Exemestane Approved, Investigational 107868-30-4 60198
23
Sirolimus Approved, Investigational 53123-88-9 5284616 6436030 46835353
24
Cisplatin Approved 15663-27-1 84093 441203 2767
25
Docetaxel Approved May 1996, Investigational 114977-28-5 148124 9877265
26 Hormone Antagonists
27 Hormones, Hormone Substitutes, and Hormone Antagonists

Interventional clinical trials:


id Name Status NCT ID Phase Drugs
1 A Study of Avastin With Taxane Therapy in Patients With Triple Negative Breast Cancer Completed NCT01094184 Phase 4 bevacizumab [Avastin]
2 A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer Completed NCT01147484 Phase 2 Foretinib
3 Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer Completed NCT00479674 Phase 2 Abraxane;Bevacizumab;Carboplatin
4 Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Active, not recruiting NCT01997333 Phase 2 CDX-011;Capecitabine
5 Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer Not yet recruiting NCT03301350 Phase 2 Carboplatin;Paclitaxel;Doxorubicin;Cyclophosphamide
6 Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis Completed NCT01377363
7 Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer Recruiting NCT02875951
8 Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer Available NCT01216111 Paclitaxel Cisplatin

Search NIH Clinical Center for Her2-Receptor Negative Breast Cancer

Genetic Tests for Her2-Receptor Negative Breast Cancer

Anatomical Context for Her2-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Her2-Receptor Negative Breast Cancer:

39
Breast

Publications for Her2-Receptor Negative Breast Cancer

Variations for Her2-Receptor Negative Breast Cancer

Expression for Her2-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Her2-Receptor Negative Breast Cancer.

Pathways for Her2-Receptor Negative Breast Cancer

Pathways related to Her2-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.1 BCL2L1 ERBB2
2 11.96 BCL2L1 ERBB2
3
Show member pathways
11.85 BCL2L1 ERBB2
4
Show member pathways
11.61 BCL2L1 ERBB2
5
Show member pathways
11.47 BCL2L1 ERBB2
6
Show member pathways
11.38 BCL2L1 ERBB2
7 10.49 BCL2L1 ERBB2

GO Terms for Her2-Receptor Negative Breast Cancer

Cellular components related to Her2-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 8.62 BCL2L1 ERBB2

Biological processes related to Her2-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 8.62 BCL2L1 ERBB2

Molecular functions related to Her2-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 8.62 BCL2L1 ERBB2

Sources for Her2-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....